


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition having ER α agonist activity and having ER β antagonist activity, comprising:

a steroid compound satisfying the following structural formula:



wherein:

one of X and Y is OH, the other being H;

R₃ is H or COR'₃, with R'₃ being alkyl or aryl;


R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl; R₁₁ is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to [9] 6 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated, and

a pharmaceutical acceptable auxiliary.


2. (Currently Amended) The pharmaceutical composition according to claim [1] 4, wherein R₁₁ is selected from the following group of side-chain structures selected from the group consisting of

U.S. Serial No. 09/831,954

{



]



3. (Cancelled)

4. (Currently Amended) The pharmaceutical composition according to claim [3] 1, wherein the longest chain in R₁₁ comprises 5 carbon atoms.

5. (Cancelled).

6. (Cancelled).


U.S. Serial No. 09/831,954

7. (Currently Amended) A method for treating estrogen deficiency disorders, comprising:

administering to a patient afflicted with an estrogen deficiency disorder a[n]
therapeutically effective amount of the pharmaceutical composition of claim 1.

8. (Currently Amended) A method of treating estrogen deficiency disorders by inducing ER α
agonist activity and ER β antagonist activity in a patient in need thereof, comprising:

administering a therapeutically effective amount of a steroid compound satisfying the
following structural formula:



formula I

wherein:

one of X and Y is OH, the other being H;

R₃ is H or COR'₃, with R'₃ being alkyl or aryl;

R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl;

R₁₁ is a hydrocarbon group, which may be linear or branched, comprising one single
linear chain having a length of from 5 to [9] 6 carbon atoms as the longest chain on carbon atom
no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated.

9. (Canceled).


10. (Canceled).

11. (Canceled).

U.S. Serial No. 09/831,954

12. (Canceled).

13. (Currently Amended) A steroid compound having ER α agonist activity and having ER β antagonist activity and satisfying the following structural formula:



formula I

wherein:



one of X and Y is OH, the other being H;

R₃ is H or COR'₃, with R'₃ being alkyl or aryl;

R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl; R₁₁ is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to [9] 6 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated.

U.S. Serial No. 09/831,954

14. (Currently Amended) The steroid compound according to claim [13] 16, wherein R_{11} is selected from the following group of side-chain structures selected from the group consisting of



15. (Cancelled)

16. (Currently Amended) The steroid compound according to claim [15] 13, wherein the longest chain in R_{11} comprises 5 carbon atoms.